Genetic studies in osteoporosis - The end of the beginning by Duncan, Emma & Brown, Matthew
Page 1 of 8
(page number not for citation purposes)
Available online http://arthritis-research.com/content/10/5/214
Abstract
Osteoporosis and disorders of bone fragility are highly heritable,
but despite much effort the identities of few of the genes involved
has been established. Recent developments in genetics such as
genome-wide association studies are revolutionizing research in
this field, and it is likely that further contributions will be made
through application of next-generation sequencing technologies,
analysis of copy number variation polymorphisms, and high-
throughput mouse mutagenesis programs. This article outlines
what we know about osteoporosis genetics to date and the
probable future directions of research in this field.
Introduction
Ninety years ago a major debate took place between the
Mendelians and the Biometricians. Mendel’s laws of
inheritance (with their clear phenotype-genotype correlation)
were inadequate to explain heritable and normally distributed
quantitative traits such as height, bone mineral density
(BMD), and weight. The elegant solution to this problem was
that both parties were right; single genes cannot underlie
inheritance of complex quantitative traits, but such traits arise
due to the action of multiple genes, each inherited in
Mendelian fashion and each exerting their individual effect
upon the ultimate phenotype. Over the past century many
monogenic diseases with classical Mendelian inheritance
have successfully been mapped, but progress in dissection
of quantitative trait loci has - until very recently - been frankly
disappointing. Now, quantum leaps in genotyping and
bioinformatics capacity have at last provided an opportunity
to unravel the genetic basis of quantitative traits that underlie
human disease.
Osteoporosis represents a paradigm in this area: a common
and disabling disease in which the phenotype is caused by
the effects of multiple quantitative trait loci. Approaches to
identify genes in which rare mutations have a large pheno-
typic effect had been extremely successful in mapping
monogenic bone diseases (for example, osteoporosis-
pseudoglioma), and certainly such genetic studies identified
hitherto unexpected pathways that also contribute to osteo-
porosis. However, until very recently, there had been little
return from extensive efforts to identify common genetic
polymorphisms in the multiple genes, each of small individual
effect, that ultimately result in the phenotype of osteoporosis.
It is therefore illuminating to review the genetics of osteo-
porosis not only in its specifics but also as a model for the
dissection of other complex genetic disorders - from genetic
epidemiology, candidate gene association studies, and
linkage studies to whole-genome association studies - and to
consider future directions.
The problem
Osteoporosis is a common condition of elderly men and
women, which manifests clinically by minimal trauma fractures,
particularly vertebral and hip fracture. Almost a quarter of
European women aged over 50 years are osteoporotic
according to World Health Organization criteria for BMD
(t-score < -2.5), and the remaining lifetime risk for any
osteoporotic hip and vertebral fracture in 50-year-old
Caucasian women is 39% [1]. Osteoporosis is not confined
to women, as is evident particularly in older age groups, in
which up to 40% of hip fractures occur in men [2].
The economic and social costs of osteoporosis represent a
huge drain of health resources. In 2005 there were approxi-
mately 2 million osteoporotic fractures in the USA, with health
care costs estimated at US$17 billion [3]. This cost was
expected to rise by 50% by 2025. In Sweden osteoporotic
fracture is responsible for more hospital bed-days than breast
cancer and prostate cancer combined [4]. Osteoporosis is
not just a problem for the developed world. Rapid population
growth and aging populations in both developed and
developing countries mean that worldwide osteoporotic
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fracture rates are expected to increase. The brunt of these
costs will be faced by developing countries that are least
equipped to cope.
Currently, most therapeutic options retard the rate of bone
loss but they do not convert osteoporosis back to normal
bone mass. Only a few anabolic agents exist, although
generally such options are too costly to be practicable, even
for wealthy countries. Current screening methods to identify
at-risk individuals have only moderate predictive capacity and
as such are not suitable for general population use. The only
hope to reverse the oncoming worldwide hip fracture tsunami
will be if radical changes are made in our understanding,
prevention, and treatment of osteoporosis. Genetics research
offers the potential to elucidate the disease process more
fully, to identify new targets for therapeutic intervention, and
to refine prognostic tests in order to improve targeting of
primary prevention measures to those most in need.
Genetic epidemiology
The first step in any condition thought to have an underlying
genetic aetiology is to establish whether a trait (such as low
BMD or fracture) really is heritable. From there, modeling can
predict the likely mode of inheritance, demonstrate the
appropriate method for investigation (for instance, family
versus general population, selected versus nonselected
population), and inform power calculations to ensure that an
appropriate study of adequate size is performed.
Twin and family studies have demonstrated that osteoporosis
is highly familial, and that the tendency of the condition to run
in families is predominantly due to genetic factors. This is true
of a wide range of osteoporosis-related phenotypes, inclu-
ding BMD, bone turnover, and skeletal dimensions asso-
ciated with growth and fracture risk [5-8], as well as fracture
risk itself [9].
There has been extensive debate and research within the
bone research community about the optimal phenotype to
study. The ultimate goal of research in osteoporosis genetics
is to identify genes that increase bone fragility. It would
therefore seem enticing to study fracture as the primary
outcome variable. However, fractures can occur for a wide
variety of reasons, some of which are unrelated to bone
fragility, and it is likely to prove genetically more complex than
intermediate bone phenotypes, such as BMD.
BMD (as measured using dual energy x-ray absorptiometry) is
the screening tool most commonly used to identify patients
with osteoporosis and who are at increased risk for low-
trauma fracture. The heritability of BMD, measured using a
variety of methods in twin and intergenerational studies, has
been shown to be very high. Studies of female twins have
shown heritability of BMD to be 57% to 92% [10-12],
including studies of postmenopausal twins [13]. Estimates
from intergenerational family studies have also identified
substantial heritability of BMD (44% to 67%) [14-16].
Several segregation studies, in families drawn from the
general population, and ascertained with probands with more
severe phenotypes, have demonstrated that the majority of
the heritability of BMD is polygenic [14,16-20]. In specific
populations substantial monogenic effects have been
observed, but this has always been on the background of
predominantly polygenic effects [19,21-23].
Therefore most genetic studies in osteoporosis to date have
focused on the phenotype of BMD, because it is highly
heritable, easy to measure, and has an established strong
relationship with fracture risk. However, areal BMD (bone
quantity per unit bone area measured) does not provide
information regarding bone distribution (between cortical and
cancellous compartments) or bone microarchitecture. Large
and small bones with different volumetric BMD (bone quantity
per unit bone volume measured) and fracture risk may have
similar areal BMD. Methods to determine bone architectural
measures and bone fragility indices from areal BMD scans
make inappropriate assumptions about similarity of bone
shape between individuals, and therefore have not proven
better predictors of fracture risk than areal BMD itself.
There has been significant interest in noninvasive assessment
of bone microarchitecture. Data from murine studies in
particular indicate that although a large proportion of genetic
variants can be identified by studies of BMD alone, significant
additional information can be obtained with use of more
informative bone imaging modalities, such as quantitative
computed tomography scanning and magnetic resonance
imaging. These methods are still in development, however,
and will not be suitable for large-scale genetic studies until
there is better standardization of measures, and until their
genetic epidemiology and clinical significance are better
established in humans.
Fracture risk is known to run in families, with the relative risk
ratio of a fracture in a first-degree relative ranging from 1.3 to
2.4, varying according to the type of relative pair and site of
fracture [24,25]. Fracture heritability studies in twins and
families have generally found more limited heritability than for
BMD, with the possible single exception of hip fracture in
younger cohorts (age <69 years). In a national Finnish cohort
of 15,098 twins [26], no significant increase in monozygotic
twin concordance for fracture was observed. The findings of
this study have been debated, and a reanalysis suggested
that the data were consistent with a 35% heritability of
fracture liability (significance level not reported) [27]. A study
of 6,750 British twins [28] found significant heritability of
54% for Colles’ fracture in women. Michaelson and
coworkers [29] studied 33,432 Swedish twins and reported
age-adjusted heritability of any fracture of 16%, osteoporotic
fractures of 27%, and hip fracture of 46%. A significant age
interaction was observed, with the heritability of fracture
being highest when the fracture occurred at a younger age
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(heritability of 68% at age <69 years), and no heritability
observed at older ages, when most hip fractures occur
(heritability 3% at age >79 years). Deng and colleagues [25]
demonstrated low heritability of Colles’ fracture in a study of
6,274 sisters or mothers of women who had had a previous
Colles’ fracture (heritability 25.4%; significance level not
reported). In a separate study of 50 Caucasian families [9],
they demonstrated no significant heritability of wrist and
spinal fractures, and heritability of hip fracture was only of
marginal significance (P = 0.048, uncorrected for the
multiple, albeit correlated, phenotypes studied). That study,
and the British twin study referred to above, suggested that
the genetic correlation between hip fracture and BMD was
low. This appears to contradict several seminal reports on the
genetic epidemiology of osteoporosis, demonstrating that
premenopausal daughters of mothers with osteoporotic
fracture have low BMD [30-32].
Overall, the fracture studies suggest that fracture has a lower
heritability than BMD, particularly among the elderly. Thus,
although it is clearly important to determine whether BMD-
associated polymorphisms influence bone fragility (the
ultimate question), the most powerful approach is likely to be
initial screens targeting genes that affect BMD, with
subsequent testing to determine the relevance of such genes
to fracture. The obvious disadvantage of this approach is that
if genes influence bone fragility and fracture risk independent
of BMD, then this approach will not identify them. However,
the evidence from BMD and fracture associated genes to
date is that nearly all BMD-associated genes are also fracture
associated.
What genes are known to cause osteoporosis?
Until the development of genome-wide association studies,
researchers employed family-based linkage techniques and
conducted candidate gene association studies in their valiant
attempts to identify osteoporosis genes. Monogenic skeletal
diseases affecting BMD are summarized in Table 1; genetic
associations with general community BMD are summarized
elsewhere [33]. As was the general experience with these
approaches in other complex genetic diseases, the signal-to-
noise ratio was not sufficient to permit robust identification of
any particular genes involved, with one notable exception -
the gene encoding lipoprotein-related receptor protein 5 (LRP5).
The role played by this gene in bone was first identified from
rare monogenic diseases, using classical linkage approaches
followed by fine mapping and candidate gene screening.
Inactivating mutations cause the autosomal-recessive condi-
tion osteoporosis-pseudoglioma, with low BMD observed in
obligate carriers [34]. Activating mutations result in the
autosomal-dominant conditions of high bone mass syndrome
[35,36]. Subsequent studies rapidly demonstrated that the
gene played a significant role in the general population
[37,38], a finding also confirmed in Asian populations [39-41].
Association was also observed with fracture risk [42,43]. The
association of LRP5 with bone density is apparent even in
childhood, indicating a likely effect on bone accrual [37,44].
Carriers of LRP5 variants have BMD 0.17 to 0.57 standard
deviations away from the population mean [45,46].
As discussed below, two studies [46,47] recently demon-
strated association of LRP5 with BMD, achieving genome-
wide significance (P < 10-7). The importance of these studies
is not just in confirming the significance of LRP5, which was
already established: rather, they serve as proof-of-concept
that whole-genome-wide association approaches success-
fully identify quantitative trait loci that underlie BMD and
osteoporosis.
These genetic findings have stimulated major research
programs into the LRP5/Wnt signaling pathway as a major
pathway in skeletal development and as a potential thera-
peutic target for osteoporosis. Of particular interest are
treatments targeting sclerostin (encoded by the gene SOST),
which is thought to inhibit LRP5. Mutations in SOST cause a
high bone mass syndrome and van Buchem disease, which is
a form of osteopetrosis with low fracture risk [48,49].
Common polymorphisms of SOST have also been demon-
strated to be associated with general population variation in
BMD [45,50], although this has been less well studied than
LRP5. Anti-sclerostin antibodies are currently in clinical trials
and are showing promise as anabolic agents in osteoporosis.
Thus, new therapeutic modalities are already in place as a
direct consequence of genetic research in osteoporosis.
A large number of other candidate genes have been
implicated in one study or another as being associated with
osteoporosis. Many of these are likely to be true positive
findings, but in our opinion few have sufficiently robust
evidence to be considered ‘established’, without needing
further confirmation. As such, their significance is currently
hard to judge. Similarly, although several areas have been
linked with BMD in family studies, in no case has the
evidence of linkage been sufficiently strong as to be
considered robust, and to date no clear candidate gene has
been identified from this approach as contributing to BMD in
the general population. Consequently, research in osteo-
porosis genetics has moved to the more powerful and
comprehensive approach of genome-wide association
studies to make progress.
Genome-wide association studies and
osteoporosis
Several groups worldwide are currently performing genome-
wide association studies in osteoporosis, mostly studying
general population cohorts, particularly focusing on BMD. An
early screen from the Framingham study [51] lacked sufficient
marker density and statistical power, and no findings of
genome-wide significance were reported. Two recent
studies, examining larger cohorts and using denser marker
sets, have been more successful.
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deCODE Genetics [52] studied 5,861 men and women from
the general population, initially testing more than 300,000
single nucleotide polymorphisms (SNPs), and then following
up 74 SNPs in a further cohort of 7,925 Icelandic, Australian,
and Danish individuals. Five regions were identified that
achieved genome-wide significance for association with
BMD. In two cases, these SNPs were in genes that are
known to be involved in bone development or turnover,
including RANKL (encoding receptor activator of nuclear
factor-κ) and its antagonist OPG (encoding osteoprotegerin).
Two novel regions included an area on chromosome 1p36
close to the gene ZBTB40 (encoding zinc finger and ETB
domain containing 40) and, somewhat surprisingly, the major
histocompatibility complex. Significant association was also
seen near to ESR1 (encoding estrogen receptor-α), a gene
previously associated with low BMD. However, all bar one of
the associated markers lie not in ESR1 itself but in an open
reading frame gene C6orf97, which is currently of unknown
expression and function. This may prove to be the primary
associated gene.
Notable results were also seen for SNPs in a number of other
candidate genes previously studied in osteoporosis, although
not achieving genome-wide significance in this study. These
included SNPs in SOST, in the glucocorticoid receptor gene
NR3C1 (in the top 500 BMD-associated SNPs overall), and
in the vitamin D receptor gene and LRP5 (in the top 1,000
SNPs). It is therefore likely that other true osteoporosis-
associated SNPs will be identified among these less strongly
associated markers.
The study also investigated association with fracture, in a
cohort including a total of 4,406 fracture cases and 36,785
control individuals [52]. No gene achieved genome-wide
significance for fracture, but moderate levels of association
(P = 10-3 to 10-4) were seen for the 1p36 region, the major
histocompatibility complex, RANK, and two regions not initially
detected through association with BMD, namely 2p16 and
11p11 (the latter containing the gene LRP4). When tested in
the overall BMD cohort, these regions did achieve moderate
level association with BMD (2p16, P = 8 × 10-7; LRP4, P = 3
× 10-4). Thus, no gene was identified to have significant
association with fracture but not with BMD. This lends support
to the approach of studying BMD as the primary phenotype.
One further point to note illustrates the importance of
adequately powered studies of sufficient marker density.
ESR1 variants associated with BMD were not associated
Arthritis Research & Therapy    Vol 10 No 5 Duncan and Brown
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Table 1
Major monogenic high and low bone mass syndromes
Gene Encoded protein Bone disorder OMIM ref.
COL1A1 Col1a1 chain of type 1 collagen Osteogenesis imperfecta 166200
COL1A2 Col1a2 chain of type 1 collagen Osteogenesis imperfecta 120160
CRTAP Cartilage associated protein Osteogenesis imperfecta type VII 605497
LEPRE1 Prolyl 3-hydroxylase Osteogenesis imperfecta type VIII 610339
PLOD2 Lysyl hydroxylase-2 Bruck syndrome (osteogenesis imperfecta with 601865
joint contractures) type 2
CA2 carbonic anhydrase II Osteopetrosis (autosomal recessive) 611492
TCIRG1 Vacuolar proton pump Osteopetrosis (autosomal recessive) 604592
CLCN7 Chloride channel 7 Osteopetrosis (both autosomal recessive and 602727
autosomal dominant forms)
OSTM1 Osteopetrosis-related transmembrane protein 1 Osteopetrosis (autosomal recessive) 607649
LRP5 Low density lipoprotein-receptor related protein 5 Osteoporosis-pseudoglioma syndrome 603506
LRP5 Low density lipoprotein-receptor related protein 5 High bone mass syndrome
SOST Inhibitor of Wnt signalling to osteoblasts von Buchem disease and sclerosteosteosis 605740
OPG (TNFRSF11B) Osteoprotegerin Juvenile Paget’s disease (hereditary 602643
hyperphosphatasia)
RANK (TNFRSF11A) RANK Familial expansile osteolysis 603499
ALPL Tissue-nonspecific (bone/liver/kidney) alkaline Hypophosphatasia 171760
phosphatase
CASR Calcium-sensing receptor Neonatal hyperparathyroidism 601199
CTSK Cathepsin K Pyknodysostosis 601105
with fracture; this is in disagreement with a prospective meta-
analysis of 18,917 individuals performed by the GENOMOS
consortium [53], which identified association with fracture
but not BMD. The meta-analysis studied two intronic SNPs in
ESR1, neither of which exhibited any association in the
deCODE study. The difference in the findings probably
relates to the low coverage of ESR1 genetic variation in the
GENOMOS study, which was estimated at only about 30%
[54].
The effect size of the fracture associated variants in the
deCODE study [52] was small, with risk ratios ranging
between 1.06 to 1.15. Individually, they are not of great use
in prediction of fracture risk, which will probably require
computation of risk from combinations of markers. The
current capacity of these tests to predict fracture is illustrated
in Figure 1. Using the findings from the discovery component
of the study, we calculated the posterior probability of a
fracture for allele carriers of the five SNPs most strongly
associated with fracture (assuming a dominant model, Hardy-
Weinberg equilibrium, and no interaction between markers
[that their effects are additive]). This combination was
associated with a likelihood ratio of fracture of 2.25 (the risk
of fracture was increased by 2.25 in carriers of all five SNPs)
and a likelihood of fracture of 0.75 in those who did not carry
the SNPs. The combination of carriage of all five SNPs was
expected to be present in 50% of fracture cases and 47.5%
of control individuals, and thus is informative for a large
proportion of the population. With increasing numbers of
markers available, better predictive performance will be
possible, although larger combinations of markers will be
relevant to smaller numbers of people. How such genetic
tests interact with traditional osteoporosis risk factors (such
as BMD) has yet to be established.
In the other genome-wide association study recently
published [47], 2,094 twins from the TwinsUK cohort were
examined, and then a two-phase replication study performed
in further BMD cohorts (n = 4,877 total) and for association
with fracture (n = 660 fractures, n = 6,639 nonfracture controls).
Two genes reached genome-wide significance, namely LRP5
and OPG. Marginal fracture association was also observed
(P = 0.006) in carriers of risk alleles at both genes, but the
effect size of this association was large (odds ratio = 1.33)
and combination common (22%), suggesting that it may be a
useful prognostic test if the fracture association can be
confirmed.
These studies illustrate the massive sample sizes required to
identify osteoporosis genes, particularly if fracture is used as
the study end-point. Studies of younger fracture cohorts are
likely to be more fruitful, given the greater heritability
suggested for hip fracture in younger cases, but these will be
harder to recruit, because most fractures occur in older age
cohorts. The small effect size seen with the fracture-
associated variants indicates that future studies will need to
be adequately powered to detect variants with odds ratios
lower than those observed here, and will thus need to be
extremely large. For example, assuming an equal number of
cases and controls, an SNP with minor allele frequency of
0.25 in linkage disequilibrium with a fracture-associated SNP
with D’ = 0.8, and a statistical threshold for significance of
P = 10-7, for a marker with an additive relative risk of 1.1 more
than 17,000 fracture cases will be required. The genetic
assumptions underlying this calculation are actually opti-
mistic. Much larger numbers will be required if the associated
variants are less common, if the mapping SNP and fracture-
associated SNP have different allele frequencies, or if gene-
gene interactions are involved. In reality, the numbers
required will be beyond the reach of individual studies, and
large consortia and meta-analytical methods will be required
to achieve adequate power. The genetics community is well
aware of this, and the recently established European Union
funded ‘Genetic Factors in Osteoporosis’ (GEFOS)
consortium has rapidly established itself as the central
organization for such efforts worldwide.
Future directions
There is little doubt that genome-wide association studies will
identify more genes that are involved in bone fragility than
those that have been reported so far. Genome-wide
association analysis in unselected populations has proven to
Available online http://arthritis-research.com/content/10/5/214
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Figure 1
Fracture risk given genetic marker findings. Presented is the post-test
probability of fracture given the pre-test risk and findings at five most
strongly fracture-associated SNPs in deCODE osteoporosis genome-
wide association study [52]. P(F+/MARKERS+) indicates the
probability of fracture in carriers of all five SNP risk alleles.
P(F-/MARKERS-) indicates the probability of no fracture in individuals
negative for all five SNP risk alleles. P(F-/MARKERS+) indicates the
probability of fracture in individuals negative for all five SNP risk alleles.
P(F+/MARKERS-) indicates the probability of fracture in carriers of all
five SNP risk alleles. SNP, single nucleotide polymorphism.
be a powerful method with which to identify common genes
of moderate effect size. The studies performed to date are
not sufficiently powered to identify genes of smaller
population effect, and may not identify some forms of human
genetic variation that are likely to influence bone fragility. No
single approach is likely to identify all bone fragility genes,
and a variety of different methods are either being developed
or are in use to tackle the problem.
The usual mantra for complex diseases is that larger studies
are needed and are likely to make many further contributions
to what we know. Size isn’t everything, however; it is equally
likely that more efficient study designs of selected cohorts
aimed at maximizing the power to detect association will
make further significant discoveries, and at considerably
lower genotyping cost than simply increasing the sample size.
In particular, cohorts recruited to minimize genetic hetero-
geneity are likely to be valuable. The genetic control over
skeletal development is known to vary between sites and
sexes, and it is likely that genes make different contributions
at different ages. Thus, cohorts recruited to investigate
osteoporosis genetics focusing on a particular site, age, and
sex are likely to have greater power to identify genes than
studies of cohorts recruited unselected from the general
population. Our group recently demonstrated this with a proof-
of-principle study [45], which easily confirmed the known
association of LRP5 with BMD in a cohort of just 320
postmenopausal women selected for extreme BMD at the hip.
Meta-analysis may also produce findings that individual
screens have missed. Although in the past competition
between groups hindered data sharing for meta-analysis,
there is a solid recognition among osteoporosis researchers
that collaboration and open data sharing will be essential
both for gene discovery and for replication.
Genetics research is technology driven. Genome-wide
association analysis was made possible by chip-based SNP
genotyping technology. A further genetics revolution is being
brought about by the development of next-generation
sequencers capable of producing up to 20 gigabases per
run, which has reignited interest in monogenic diseases. It is
likely that in a high proportion of individuals with extreme
phenotypes (such as extreme high or low BMD in humans) a
monogenic - usually rare - mutation underlies their extreme
phenotype, as has been demonstrated, for example, with
osteogenesis imperfecta type 1 and Marfan’s syndrome.
When there were not enough family members to help localize
the gene by traditional linkage methods, or the individual did
not fit a known syndrome that would allow population studies
to be conducted, the mutations in these cases could not be
identified. With the new sequencing capacity it will be
possible to sequence extremely large proportions of the
genome (such as, for example, all exons) in a single sequen-
cing run. Such cases may be studied again, and it is highly
likely that new disease genes affecting bone fragility will be
identified, not just of relevance to these extreme phenotypes
but also to control of BMD in the general population.
Two further influences on human variation that have yet to be
addressed significantly in osteoporosis include copy number
variation (CNV) and gene-gene interaction. CNV is known to
be common throughout the genome and is likely to influence
gene expression. High-throughput, accurate genotyping
methods for CNV are still in development, but array-based
methods show promise. Gene-gene interaction is known from
mouse models to influence skeletal development significantly
[55] and is thus likely also to contribute to human skeletal
development. All genome-wide association studies to date
have been single-marker studies, but it is likely that once
sufficient cases have been screened, more complex genetic
models will be tested.
Mouse genetics to date has contributed much to what we
know about the genetic epidemiology of bone fragility and
associated phenotypes, such as BMD and bone micro-
architecture. Hypothesis-free gene mapping of bone fragility
genes has made slow progress though. Congenic
approaches, investigating the genetic causes of differences in
bone parameters between inbred mouse strains, has yielded
some success in the identification of Alox12, implicating the
lipoxygenase system in osteoporosis [56]. However, the
inbred nature of the mice restricts the mapping resolution that
can be obtained, and most established linkages with bone
parameters have not resulted in identification of the causative
gene. An alternate approach is ENU mutagenesis, in which
male mice are treated with the alkylating agent ethinyl-
nitrosourea, causing point mutations in sperm DNA. Offspring
of these mice carry these mutations. By screening thousands
of offspring of mutagenized mice, mice with phenotypes
generally caused by monogenic point mutations caused by
the ENU can be identified. These monogenic variants are
much easier to map than congenic genes, and because the
mutations concerned are not as severe as knock-out or
knock-in methods, the models are more physiological. This
approach is being used by a number of groups worldwide to
create new mouse models of osteoporosis.
Conclusion
This is a time of great excitement in the world of genetics
generally, and in osteoporosis genetics specifically. The
publication of the Wellcome Trust Case Control Consortium
(less than 12 months ago at the time of writing) [57] was not
only an enormous leap forward in identifying that genes that
underlie complex genetic disorders such as inflammatory
bowel disease, ankylosing spondylitis, and type 1 diabetes. It
also provided proof that the approach adopted was going to
work for other complex quantitative traits such as osteo-
porosis. The success of early genome-wide association
studies in osteoporosis supports this position. Already, these
studies have identified novel pathways that contribute to
control of BMD and bone fragility with possible therapeutic
Arthritis Research & Therapy    Vol 10 No 5 Duncan and Brown
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targets. The possibility of genetic prognostic tests, adding to
existing predictive information from BMD, is likely to become
a reality within the next decade. Hopefully, the frustrations of
the past few decades have taught the genetics community
that careful phenotyping, sophisticated study design, ade-
quately powered cohorts, and collaboration are key elements
to successful gene identification. We have finished with the
beginning and can now see ways and means to achieve a
successful future.
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